Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From Nanobiotix

Bringing A Different Science Into Solid Tumor Treatment

Depending on the regulatory jurisdiction, Nanobiotix’s radiation-activated cancer nanotechnology may be a drug or a device. But regardless of classification, it offers a physical solution to problems that chemistry and biology cannot solve.

Innovation Cancer

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.

Cancer Companies

Tech Transfer Roundup: MD Anderson Inks Set Of IO Deals Covering US, UK, Japan, China

Three separate agreements team the innovative cancer research center with Takeda, Artios/ShangPharma, and Ziopharm. Hoth continues busy deal-making year by licensing gene therapy from North Carolina State.

Deals Research and Development Strategies

Nanobiotix CEO: Curadigm Spin-Out Platform Could ‘Redefine’ Drug-Body Balance

Laurent Levy tells Scrip Nanobiotix’s freshly-created subsidiary Curadigm aims to improve bioavailability of nanomedicines by reducing liver and spleen toxicity and accumulation.

Companies Drug Delivery
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Nanotechnology, Chips, etc.
  • Other Names / Subsidiaries
    • Curadigm
UsernamePublicRestriction

Register